Pablo Marti Andres
Affiliated to research
Dr. Pablo Martí Andrés is currently a Postdoctoral Researcher in Prof. Elias Arnér's laboratory. Pharmacist by training, he obtained his International Ph.D. Degree in 2020. Dr. Martí Andrés' background in oxidative stress and redox signaling, his experience with in vitro and in vivo models of acute inflammation and cancer, and his hunger for knowledge make him a thorough and versatile researcher.
Dr. Martí Andrés is thrilled to be back in Stockholm and hopes his work could be translated into clinical practice to expand current therapeutic choices and improve patient outcomes.
Dr. Martí Andrés' research currently focuses on the role of trace elements in the pathophysiology of cancer, especially in how varying concentrations of Se, Cu, and Zn modulate redox signaling pathways in cancer cells.
Cancer is a life-threatening disease with an increasing incidence worldwide. Previous studies suggest there are remarkable shifts in homeostasis, steady-state levels, and dynamics of trace elements in patients diagnosed with cancer. Unlike copper (Cu), which is usually increased, the levels of zinc (Zn) and selenium (Se) are often lower in the serum of cancer patients. In colorectal and breast cancers, elevated serum Cu correlates with the stage of the disease and its progression. In addition, tumor tissue appears to specifically accumulate Cu and Se, and in some tumor types, also Zn. The underlying molecular mechanisms explaining these effects are however essentially unknown and they are the focus of Dr. Martí Andrés' research project. Understanding these complex interactions and their effects may lead to identifying new potential targets for drug therapy, improving the lives of cancer patients.
Furthermore, Dr. Martí Andrés continues studying thioredoxin-related protein of 14 kDa (TRP14) in the context of the regulation of cellular redox functions –a project he initiated during his Ph.D. studies, and that is allowing to describe new functions of this recently-discovered protein.